EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities

Eduardo Agostinho Freitas Fernandes, Joy van Oudtshoorn, Andrew Tam, Liliana Carolina Arévalo González, Erwin Guzmán Aurela, Henrike Potthast, Katalina Mettke, Ryosuke Kuribayashi, Kohei Shimojo, Miho Kasuga, Lázaro Morales, Zulema Rodríguez und 18 weitere

Journal of Pharmacy & Pharmaceutical Sciences · 2024

DOI: 10.3389/jpps.2024.12398 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2024. Verfasst von Eduardo Agostinho Freitas Fernandes und 29 weiteren Autor:innen. Beteiligte Einrichtung: Agência Nacional de Vigilância Sanitária, Brasília, Brazil. Hauptthemen laut MEDLINE: Drugs, Generic, Research Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bioequivalence (BE) studies are considered the standard for demonstrating that the performance of a generic drug product in the human body is sufficiently similar to that of its comparator product. The objective of this article is to describe the recommendations from participating Bioequivalence Working Group for Generics (BEWGG) members of the International Pharmaceutical Regulators Programme (IPRP) regarding the conduct and acceptance criteria for BE studies of immediate release solid oral dosage forms. A survey was conducted among BEWGG members regarding their BE recommendations and requirements related to study subjects, study design, sample size, single or multiple dose administration, study conditions (fasting or fed), analyte to be measured, selection of product strength, drug content, handling of endogenous substances, BE acceptance criteria, and additional design aspects. All members prefer conducting single dose cross-over designed studies in healthy subjects with a minimum of 12 subjects and utilizing the parent drug data to assess BE. However, differences emerged among the members when the drug’s pharmacokinetics and pharmacodynamics become more complex, such that the study design (e.g., fasting versus fed conditions) and BE acceptance criteria (e.g., highly variable drugs, narrow therapeutic index drugs) may be affected. The survey results and discussions were shared with the ICH M13 Expert Working Group (EWG) and played an important role in identifying and analyzing gaps during the harmonization process. The draft ICH M13A guideline developed by the M13 EWG was endorsed by ICH on 20 December 2022, under Step 2 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericResearch DesignHumansTherapeutic Equivalency

Stichwörter der Autor:innen

ICHIPRPbioequivalenceimmediate releasestudy design

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Agência Nacional de Vigilância Sanitária, Brasília, Brazil.
  • South African Health Products Regulatory Authority, Pretoria, South Africa.
  • Health Canada, Ottawa, ON, Canada.
  • Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Bogota, Colombia.
  • Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Förderung

  • World Health Organization

Zitieren

APA

Fernandes, E. A. F., van Oudtshoorn, J., Tam, A., González, L. C. A., Aurela, E. G., Potthast, H., Mettke, K., Kuribayashi, R., Shimojo, K., Kasuga, M., Morales, L., Rodríguez, Z., Jones, B., Ahn, C., Yun, E., Kim, S. H., Rodrigues, C., Tiong, T., Crane, C., …, & Alharf, A. (2024). The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2024.12398

Vancouver

Fernandes EAF, van Oudtshoorn J, Tam A, González LCA, Aurela EG, Potthast H, et al. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. Journal of Pharmacy & Pharmaceutical Sciences. 2024. doi:10.3389/jpps.2024.12398

BibTeX
@article{Fernandes2024,
  author = {Fernandes, Eduardo Agostinho Freitas and van Oudtshoorn, Joy and Tam, Andrew and González, Liliana Carolina Arévalo and Aurela, Erwin Guzmán and Potthast, Henrike and Mettke, Katalina and Kuribayashi, Ryosuke and Shimojo, Kohei and Kasuga, Miho and Morales, Lázaro and Rodríguez, Zulema and Jones, Ben and Ahn, Choongyul and Yun, Eunju and Kim, So Hee and Rodrigues, Clare and Tiong, Toh and Crane, Christopher and Walther, Chantal and Roost, Matthias S and Chen, Tzu-Ling and Hsu, Li-Feng and Braddy, April C and García-Arieta, Alfredo and Abalos, Ivana and Divinsky, Milly and Alsuwyeh, Abdulaziz and Alzenaidy, Bader and Alharf, Adel},
  title = {The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2024},
  doi = {10.3389/jpps.2024.12398}
}
Kostenlos starten →